A. Portal

Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'

J. Taieb, J. Bachet, S. Pernot, 2016, British journal of cancer.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

N. Siauve, P. Rougier, J. Taieb, 2014, Clinics and research in hepatology and gastroenterology.

FiLaC® and Crohn’s disease perianal fistulas: a pilot study of 20 consecutive patients

V. de Parades, A. Portal, É. Pommaret, 2019, Techniques in Coloproctology.

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort

F. Bonnetain, P. Hammel, J. Taieb, 2015, British Journal of Cancer.

Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.

P. Rougier, F. Bonnetain, P. Hammel, 2015 .

Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.

N. Siauve, P. Rougier, J. Taieb, 2014, Clinics and research in hepatology and gastroenterology.